(1-Benzyl-2-ethyl-3-oxamoylindol-4-yl) acetate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (1-Benzyl-2-ethyl-3-oxamoylindol-4-yl) acetate
• 化学式: C₂₁H₂₀N₂O₄
• 分子量: 364.4
• InChiKey: FRDXFEBPDHNYLS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  91.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• REMEDIES OR PREVENTIVES FOR ISCHEMIC REFLOW FAILURE
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1157704A1

  公开（公告）日：2001-11-28

  A composition for treating or preventing ischemia reperfusion injury which contains an sPLA2 inhibitor as an active ingredient.

  一种用于治疗或预防缺血再灌注损伤的组合物，其活性成分中含有一种 sPLA2 抑制剂。
• Secreted proteins as early markers and drug targets for autoimmunity, tumorigenesis and infections
  申请人：INSTITUT PASTEUR

  公开号：EP1840573A1

  公开（公告）日：2007-10-03

  The present invention relates to a method for the early diagnosis of a disease having a pre-inflammatory phase, or for the diagnosis of a predisposition to said disease, in a mammal, prior to any clinical signs, comprising measuring the level of at least a marker protein chosen amongst the following murine proteins Pap, Reg3a, Reg2, Cel, Reg1, Tff2, Clps, Spp1, Klk9, Klk6, Rib1, Klk5, Muc1, Cckar, Ggh, Ang, Nucb2, Pnliprp2, Pla2g1b, Ela1, Ela2, 2210010C04Rik, Pnliprp1, Itmap1, Vtn, C1qb, Sycn, Amy1, Ctrb1, 1110002023Rik, 1810014L12Rik and their respective mammalian orthologs, in a body fluid or tissue sample obtained from said mammal, comparing the measured level to a reference level for said marker protein and diagnosing the later onset of said disease if the measured level is significantly superior to the reference level. The invention also encompasses related methods and uses of these early markers of diseases having a pre-inflammatory phase. A preferred mammal is human and a preferred diseases are auto-immune diseases, especially type 1 diabetes.

  本发明涉及一种在哺乳动物出现任何临床症状之前早期诊断具有炎症前阶段的疾病或诊断所述疾病易感性的方法，该方法包括测量至少一种选自下列鼠类蛋白质的标记蛋白质的水平：Pap、Reg3a、Reg2、Cel、Reg1、Tff2、Clps、Spp1、Klk9、Klk6、Rib1、Klk5、Muc1、Cckar、Ggh、Ang、Nucb2、Pnliprp2、Pla2g1b、Ela1、Ela2、2210010C04Rik、Pnliprp1、Itmap1、Vtn、C1qb、Sycn、Amy1、Ctrb1、1110002023Rik、1810014L12Rik 及其各自的哺乳动物同源物、将测得的水平与所述标记蛋白的参考水平进行比较，如果测得的水平明显高于参考水平，则诊断所述疾病的后期发病。本发明还包括这些具有前炎症阶段的疾病早期标志物的相关方法和用途。优选的哺乳动物是人类，优选的疾病是自身免疫性疾病，尤其是 1 型糖尿病。
• [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor
  申请人：Eli Lilly and Company

  公开号：EP2341045A1

  公开（公告）日：2011-07-06

  The compounds [[3-(2-amino-1,2-diooethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl]oxy]acetic acid (acyloxy) alkyl or ((alkoxycarbonyl)oxy)alkyl ester are disclosed together with the use of the indole compound for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock.

  公开了[[3-(2-氨基-1,2-二氧乙基)-2-乙基-1-(苯基甲基)-1H-吲哚-4-基]氧基]乙酸（酰氧基）烷基或（（烷氧羰基）氧基）烷基酯化合物，以及吲哚化合物用于抑制 sPLA2 介导的脂肪酸释放以治疗脓毒性休克等疾病的用途。
• METHOD FOR TREATMENT OF CHRONIC BRONCHITIS
  申请人：ELI LILLY AND COMPANY

  公开号：EP1007046A1

  公开（公告）日：2000-06-14
• EP1007046A4
  申请人：——

  公开号：EP1007046A4

  公开（公告）日：2000-11-29